

G1 to One® ENROLLMENT FORM FOR COSELA® (trilaciclib)

Fax the completed three-page enrollment form to 1-833-FAX-G121 (1-833-329-4121)

Patient First Name	Patient Last Name	Gender	Date of Birth
		Male Female	
Height (in)	Weight (lbs)	Street Address	City
State	ZIP Code	Phone #	Preferred Language
Alt. Contact First Name	Alt. Contact Last Name	Alt. Contact Relationship	Alt. Contact Phone #
2. PRESCRIBER/FACILIT	Y SETTING (*REQUIRED FIELDS	S)	
Prescriber First Name*	Prescriber Last Name*	State Where Licensed*	State License #*
Prescriber Type	NPI #*	Tax ID #*	PTAN #*
Facility Setting/Billing Entity	Facility Setting Address*	City*	State*
Infusion Clinic/ Physician Office	ZIP Code*	Primary Contact Name	Title/Role
Hospital Outpatient			
Hospital Inpatient	Primary Phone #	Primary Fax #	Primary Email
Facility Name			
3. INSURANCE INFORMA	TION		
Medicare Medic		te Other	
Please attach a copy of both sides o	of the patient's insurance card.		
Primary Insurance	Policy ID #	Group #	Phone #
Subscriber First Name	Subscriber Last Name	Subscriber Date of Birth	Patient Relationship to Subscribe
		0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Dhana #
Secondary Insurance	Policy ID #	Group #	Phone #

Email us at

Enroll@G1toOne.com

Visit us at

www.G1toOne.com

trilaciclib for injection 300 mg

Call us at 1-833-G1toOne

(1-833-418-6663)

4. CLINICAL INFORMATIO	N (*REQUIRED FIELDS)			
Primary Diagnosis ICD-10 Code*	Diagnosis of Small Cell Lung Cancer*	Treatment plan includes platinu containing regimen or topotecan		Target Start Date*
	Yes No	Yes No		
5. FINANCIAL ASSISTANC	E			
This section should only be complete is required for financial assistance.	d for financial assistance o	or enrollment into the Patient Assistance	Program (PAP). Patient f	financial information
Annual Gross Household Income	Number of	Persons in Household		
\$				
6. PRESCRIPTION INFORM	ATION FOR ELIGIBL	E UNINSURED OR UNDERINSUF	RED PATIENTS	
		support from Patient Assistance Program please attach a separate prescription in		
Medication: COSELA® (trilaciclib)	for injection, 300 mg per	vial Route of Administration: IV	/PB	
Instructions: Administer as a 30-mi	nute intravenous infusion	no more than 4 hours prior to chemothe	erapy on each day chem	otherapy is administered.
BSA m² Dosing: 240 mg/m	² Dose mg Days	s: 1-3 1-5 Other	Total Vials per Cy	cle Refills
Please list or attach a current list	of medications			
Known Drug Allergies				
I authorize Pharmacosmos Therape Setting address as part of the Pati	_	ated non-commercial pharmacy to dis	pense COSELA directl	y to the Facility
Prescriber Name (Print)		Signature (No Stamps)		Date
7. PREFERRED SHIPPING I	LOCATION (IF DIFFERE	ENT FROM Facility Setting ADDRESS)	
	Street Address			ZIP Code
Name	Street Address	City	State	ZIP Code
8. PRESCRIBER CERTIFICA	ATION AND AUTHOR	IZATION		
patient's legal representative) to reboth as provided on this form and sof the patient's insurance coveragin the Program, (4) to provide reimbform, and (5) for the other purpose and appoint the Program to convey to the dispensing pharmacy. I agree additional information relating to that no charge to the patient is provided.	elease to the patient supp such other personal healt e for COSELA, (2) to asses bursement support and or is identified on the Patient y on my behalf the prescri ee that the Program may he Program, COSELA, or t vided on a complimentar	have obtained written permission fro port program, G1 to One ("the Program" h information as the Program may need as the patient's eligibility for participal ther services to the patient in connect t Authorization for Use and Disclosure iption(s) I signed for the patient and the contact me, including without limitate the prescription(s) contained on this for y basis. I will not submit or cause to including a federal health care progra	'), the patient's personated (1) to perform a prelimition in the Program, (3) tion with the patient's personal Health Inferential Earth of the other information incidential Earth (1) and the content of	al health information, minary verification to enroll the patient prescription(s) on this ormation. I authorize cluded on this form telephone, to seek ny COSELA provided ms for payment or

Signature (No Stamps)

Email us at

Enroll@G1toOne.com

Visit us at

www.G1toOne.com



2 of 3

Date

Healthcare Professional Name (Print)

9. HIPAA RELEASE PATIENT AUTHORIZATION FOR USE AND DISCLOSURE OF PERSONAL HEALTH INFORMATION

lauthorize my healthcare providers (including pharmacy providers) and health plans to disclose my personal health information related to this prescription form or my use or potential use of COSELA®, including my personal contact information on this form (collectively, my "Information"), to the patient support program called G1 to One (the "Program") so that the Program may use and disclose the Information in order to: (1) establish my benefit eligibility; (2) communicate with my healthcare providers and health plans about my benefit and coverage status and my medical care; (3) provide support services, including facilitating the provision of COSELA to me, as well as any information or materials related to such services or Pharmacosmos products, including promotional or educational communications; (4) evaluate the effectiveness of COSELA support programs; (5) report safety information, including in communications with the US Food and Drug Administration and other government authorities; (6) contact me regarding this prescription form or my use or potential use of COSELA and provide me with related patient support communications, including through messages left for me that disclose that I take or may take COSELA; and (7) allow Pharmacosmos to analyze the usage patterns and the effectiveness of Pharmacosmos products, services, and programs and help develop new products, services, and programs, and for other Pharmacosmos general business and administrative purposes. I understand that my provider(s) may receive remuneration in exchange for the provision of my Information as authorized above, and that once my Information has been disclosed to the Program, federal privacy law may no longer restrict its use or disclosure and that it may be redisclosed to others. I also understand, however, that the Program plans to use and disclose my Information only for the purposes described above or as required by law. I understand that if I refuse to sign this Authorization, that will not affect my right to treatment or payment benefits for health care. I also understand that if I sign, I may later withdraw this Authorization by sending written notice of my withdrawal from the Program to G1 to One, PO Box 5757, Louisville, KY 40255, and that such withdrawal will not affect any uses and disclosures of my Information prior to the Program's receipt of the notice. I am entitled to a copy of this signed Authorization, which expires 10 years from the date it is signed by me or such timeframe as allowed by law. Please note documentation proving Power of Attorney may be required.

Patient Name (Print)	Patient Signature	Date							
AUTHORIZED REPRESENTATIVE CONSENT (Optional) I further authorize G1 to One to discuss my treatment with the following authorized representative(s).									
Authorized Representative (1) Name (Print)	Relationship to Patient: Spo	ouse Child Other:							
Authorized Representative (2) Name (Print)	Relationship to Patient: Spo	ouse Child Other:							

3 of 3

PHARMACOSMOS